Sinopharm Group Co. Ltd.
1099
Classement en actions
#2952
Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of... Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support to both domestic and international manufacturers and suppliers in the pharmaceutical and healthcare sectors. The Medical Devices segment is solely focused on the distribution of various medical equipment. Through its Retail Pharmacy division, Sinopharm manages and franchises a vast chain of drug stores, with an impressive 10,259 locations as of December 31, 2021. The "Other Business" segment is involved in the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core areas, the company also engages in property rental and management. It further distributes specialized items such as medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Sinopharm provides a comprehensive array of services, including IT development, medicine and health consultations, investment services, import/export facilitation for goods and technology, various business and market information consulting, and the organization of conventions and exhibitions. Moreover, it oversees medical project investments, offers related consulting, and provides technological training. Notably, Sinopharm Group has established a strategic alliance with I-Mab to enhance its commercial capabilities and accelerate its market entry strategies. Founded in Shanghai, China, in 2003, Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Prix de l'action
$2.00
Capitalisation boursière
$6.26B
Changement (1 jour)
1.95%
Changement (1 an)
-16.78%
Pays
CN
Échange Sinopharm Group Co. Ltd. (1099)
Catégorie
Healthcare
Ratio P/E pour Sinopharm Group Co. Ltd. (1099)
Ratio P/E au October 2026 TTM : 5.95
Selon les derniers rapports financiers et le cours de l'action de Sinopharm Group Co. Ltd., le ratio P/E actuel (TTM) est de 5.95. À la fin de l’année 2023, le P/E de l’entreprise était de 6.31.
Historique du ratio P/E pour Sinopharm Group Co. Ltd. de 2006 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 5.95 | -32.88% |
| 2024 | 8.86 | 40.36% |
| 2023 | 6.31 | -1.62% |
| 2022 | 6.41 | 15.78% |
| 2021 | 5.54 | -19.36% |
| 2020 | 6.87 | -3.35% |
| 2019 | 7.11 | -22.00% |
| 2018 | 9.11 | -15.07% |
| 2017 | 10.73 | -36.83% |
| 2016 | 16.98 | -11.33% |
| 2015 | 19.15 | -3.06% |
| 2014 | 19.76 | 1.48% |
| 2013 | 19.47 | -17.93% |
| 2012 | 23.72 | 3.89% |
| 2011 | 22.83 | -46.94% |
| 2010 | 43.03 | -17.01% |
| 2009 | 51.85 | 59.01% |
| 2008 | 32.61 | -38.42% |
| 2007 | 52.95 | -68.18% |
| 2006 | 166.42 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 26.02 | 337.53% |
US
|
|
| - | - |
US
|
|
| 34.08 | 472.99% |
US
|
|
| - | - |
US
|
|
| 45.62 | 667.03% |
AU
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.